Dublin, Ireland-based Endo International plc is a specialty pharmaceutical company focused on branded and generic pharmaceuticals products as well as over-the-counter medications through its operating companies. The company has several products including Lidoderm, Opana ER, Supprelin LA and Fortesta Gel in its Branded Pharmaceuticals portfolio.
Endo has implemented a growth-by-acquisition strategy. The company has acquired privately held Par Pharmaceutical, which boosted its generics portfolio and pipeline. The company also acquired a broad portfolio of branded and generic injectable and established products focused on pain, anti-infectives, cardiovascular and other specialty therapeutics areas from a subsidiary of Aspen Holdings.
Endo has been consistently beating earnings expectations. In fact, Endo posted a positive surprise in each of the trailing four quarters, with an average positive surprise of 12.3%.
Currently, Endo has a Zacks Rank #4 (sell), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Endo surpassed fourth-quarter 2016 earnings. The company reported EPS of $1.77 while our consensus called for EPS of $1.63.
Revenues: Revenues also came in above expectations. Endo posted revenues of $1.24 billion compared to our consensus estimate of $1.15 billion.
Key Stats: Revenues were up on a year over year basis due to the launch of key first-to-file generic products for Seroquel and Zetia.
2017 Guidance: Endo expects revenues in the range of $3.45 billion to $3.60 billion, lower than the 2016 revenues of $4.0 billion primarily due to the expected revenue decline in its generics base business and legacy branded pain franchise, as well as the impact of divestitures and product discontinuations. The company expects earnings in the range of $3.45 to $3.75 per share. The Zacks Consensus Estimate for earnings is $4.24 per share on revenues of $3.87 billion.
Pre-Market Trading: Shares are up around 3.5% in the pre-market trading.
Check back later for our full write up on this ENDP earnings report later!
A Full-Blown Technological Breakthrough in the Making
Zacks’ Aggressive Growth Strategist Brian Bolan explores autonomous cars in our latest Special Report, Driverless Cars: Your Roadmap to Mega-Profits Today. In addition to who will be selling them and how the auto industry will be impacted, Brian reveals 8 stocks with tremendous gain potential to feed off this phenomenon. Click to see the stocks right now >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Dublin, Ireland-based Endo International plc is a specialty pharmaceutical company focused on branded and generic pharmaceuticals products as well as over-the-counter medications through its operating companies. The company has several products including Lidoderm, Opana ER, Supprelin LA and Fortesta Gel in its Branded Pharmaceuticals portfolio.
Endo has implemented a growth-by-acquisition strategy. The company has acquired privately held Par Pharmaceutical, which boosted its generics portfolio and pipeline. The company also acquired a broad portfolio of branded and generic injectable and established products focused on pain, anti-infectives, cardiovascular and other specialty therapeutics areas from a subsidiary of Aspen Holdings.
Endo has been consistently beating earnings expectations. In fact, Endo posted a positive surprise in each of the trailing four quarters, with an average positive surprise of 12.3%.
Currently, Endo has a Zacks Rank #4 (sell), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Endo surpassed fourth-quarter 2016 earnings. The company reported EPS of $1.77 while our consensus called for EPS of $1.63.
Revenues: Revenues also came in above expectations. Endo posted revenues of $1.24 billion compared to our consensus estimate of $1.15 billion.
Key Stats: Revenues were up on a year over year basis due to the launch of key first-to-file generic products for Seroquel and Zetia.
2017 Guidance: Endo expects revenues in the range of $3.45 billion to $3.60 billion, lower than the 2016 revenues of $4.0 billion primarily due to the expected revenue decline in its generics base business and legacy branded pain franchise, as well as the impact of divestitures and product discontinuations. The company expects earnings in the range of $3.45 to $3.75 per share. The Zacks Consensus Estimate for earnings is $4.24 per share on revenues of $3.87 billion.
Pre-Market Trading: Shares are up around 3.5% in the pre-market trading.
Check back later for our full write up on this ENDP earnings report later!
A Full-Blown Technological Breakthrough in the Making
Zacks’ Aggressive Growth Strategist Brian Bolan explores autonomous cars in our latest Special Report, Driverless Cars: Your Roadmap to Mega-Profits Today. In addition to who will be selling them and how the auto industry will be impacted, Brian reveals 8 stocks with tremendous gain potential to feed off this phenomenon. Click to see the stocks right now >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>